MK-1775 is a potent and selective Wee1 kinase inhibitor with an IC50 of 5.2 nM. It abolishes cyclin-dependent kinase 1 (CDC2) activity by phosphorylation of the Tyr15 residue. It abrogates a DNA damage checkpoint (G2-phase), leading to apoptosis in combination with several DNA-damaging agents selectively in p53-deficient tumor cell lines. It is under clinical trial for advanced solid tumors.

June 21, 2017

prudect name : MK-1775 is a potent and selective Wee1 kinase inhibitor with an IC50 of 5.2 nM.
It abolishes cyclin-dependent kinase 1 (CDC2) activity by phosphorylation of the Tyr15 residue. It abrogates a DNA damage checkpoint (G2-phase), leading to apoptosis in combination with several DNA-damaging agents selectively in p53-deficient tumor cell lines. It is under clinical trial for advanced solid tumors.
MK-1775

Synonyms: CAS NO: 955365-80-7Molecular Formula: C₂₇H₃₂N₈O₂Molecular Weight: 500.6Purity: 98% minSolubility: In DMSOStorage: −20°C

web site: www.medchemexpress.com

References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1852779